Looming US-China trade talks lift Asian stock markets; China cuts interest rates – business live

Please turn on JavaScript to use this feature Please turn on JavaScript to use this feature 4m ago 04.33 EDT Wegovy maker cuts forecasts Denmark's Novo Nordisk has cut its revenue and profit forecasts for this year following disappointing sales of its weight loss drug Wegovy, as US prescriptions tailed off amid fierce competition. Booming sales of Wegovy and the diabetes medication Ozempic helped to turn the pharmaceutical firm into Europe's most valuable listed company, worth $615bn at its peak. However, prescriptions in the United States, its biggest market, have not grown since February, even though Novo Nordisk ramped up…